Elicera Therapeutics develops new cancer treatment with help of advanced cell lab in Flemingsberg
Uppsala-based Elicera Therapeutics is using the Pre-GMP core facility at Vecura in Flemingsberg as a first step in a study aimed at creating a new treatment for lymph node cancer.
The pre-GMP lab at Campus Flemingsberg makes it possible to use a new method to automate the process of genetically modifying cells for research studies.
“The facility allows us to benefit from a completely closed and automated system that reduces the workload for staff and further ensures quality,” says Magnus Essand, Research Director at Elicera.
In the Pre-GMP lab, the process can be developed and fine-tuned while staff at Vecura receive training in the new methods.
Activating the immune system
The establishment of Elicera Therapeutics was based on research conducted at Uppsala University with the aim of using modified cells – CAR-T cells – to develop new cancer treatments. Cells taken from patients develop the ability to activate the body’s own immune system in the fight against cancer.
The goal of the current study is to identify a treatment for patients with Non-Hodgkin’s lymphoma, a form of lymph node cancer.
“There are currently two approved treatments for the disease, but they don’t work for all patients. We hope that our treatment can also be used by these patients and prevent recurrence,” says Essand, adding: “We hope to develop a curative treatment for these patients.”
Elicera Therapeutics recently received a grant from the European Innovation Council (EIC) to help them grow further. In the future, there are plans to use the company’s findings to develop treatments for patients with brain cancer.
Read more on the Elicera Therapeutics homepage at: elicera.com.
BioLamina Establishes Operations in Flemingsberg – A Key Player in ATMP Development
As the world’s first and only producer of laminins, the biotechnology company BioLamina has expanded its operations and chosen to establish part of its business in Flemingsberg. Using laminins, a protein that creates an optimal environment for cells to expand and/or differentiate, they are a key player in the development of ATMPs (Advanced Therapy Medicinal Products) in Sweden and globally.
Sally Sow and Turn UP: Winners of the Flemingsberg Science Award IDEA 2024
The music world can be a challenging place, both for organizers trying to reach their audience and for music lovers searching for events that suit their taste. Sally Sow, the winner of the Flemingsberg Science Award IDEA 2024, has developed Turn Up, a platform that simplifies organizing, discovering, and participating in local music events. With a focus on inclusion and accessibility, she aims to create a music scene where everyone feels welcome.
KTH’s Technical Preparatory Year Moves to Flemingsberg – Student Numbers Expected to Double in Autumn 2025
In the autumn of 2025, KTH will relocate its Technical Preparatory Year spots from Södertälje to Flemingsberg, resulting in a significant increase in student numbers at Campus Flemingsberg. By nearly doubling available seats and introducing a new learning center model in collaboration with 3 municipalities, KTH aims to meet the growing demand for technical education in the region.
Drivhuset Stockholm – Where Future Entrepreneurs Take Their First Steps
Imagine a place where young ideas are free to grow, where passion meets ambition, and where the entrepreneurs of tomorrow take their first steps toward greatness. That’s exactly what Drivhuset Stockholm offers – a springboard for the next generation of entrepreneurs. Located on Campus Flemingsberg, we support students every day as they bring their ideas to life and build the skills needed to create real change. Our mission? To provide them with a safe, inspiring environment where they can test and develop their business ideas for real.
OptiCell Solutions – A Key Player in Cell and Gene Therapy Establishes in Flemingsberg
Flemingsberg continues to be a natural choice for knowledge-intensive and innovative businesses. OptiCell Solutions is a company that recently launched its operations at Novum Labs on Campus Flemingsberg. Founded in 2024 by specialists from Karolinska University Hospital and entrepreneurs from the Life Science industry, the company specializes in improving the availability of high-quality target cells for cell and gene therapies, a critical component of the growing ATMP (Advanced Therapy Medicinal Products) sector.
